The FDA approved Merck’s Keytruda Qlex, a subcutaneous PD-1 immune checkpoint inhibitor injection that can be administered in about a minute, enhancing treatment convenience for solid tumors. Tempus received 510(k) clearance for its RNA-based xR IVD assay enabling comprehensive genomic profiling to support precision oncology drug development. Scanogen was awarded a $2.9 million NIH grant to advance its rapid, culture-free bloodstream yeast infection test, aiming for regulatory submissions with improved clinical diagnostics.